PT771817E - Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso - Google Patents

Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso

Info

Publication number
PT771817E
PT771817E PT96500140T PT96500140T PT771817E PT 771817 E PT771817 E PT 771817E PT 96500140 T PT96500140 T PT 96500140T PT 96500140 T PT96500140 T PT 96500140T PT 771817 E PT771817 E PT 771817E
Authority
PT
Portugal
Prior art keywords
estrogen
obesity
treatment
group
estrone
Prior art date
Application number
PT96500140T
Other languages
English (en)
Inventor
Maria Alemany
Original Assignee
Oleoyl Estrone Developments S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleoyl Estrone Developments S filed Critical Oleoyl Estrone Developments S
Publication of PT771817E publication Critical patent/PT771817E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96500140T 1995-10-30 1996-10-28 Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso PT771817E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9502101 1995-10-30

Publications (1)

Publication Number Publication Date
PT771817E true PT771817E (pt) 2003-06-30

Family

ID=8291993

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96500140T PT771817E (pt) 1995-10-30 1996-10-28 Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso

Country Status (7)

Country Link
US (1) US5798348A (pt)
EP (1) EP0771817B1 (pt)
AT (1) ATE235505T1 (pt)
DE (1) DE69626927T2 (pt)
DK (1) DK0771817T3 (pt)
ES (1) ES2192221T3 (pt)
PT (1) PT771817E (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
AU4701299A (en) * 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
WO2000050067A1 (en) * 1999-02-26 2000-08-31 Saltech I Göteborg Ab Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US7025984B1 (en) * 2000-06-26 2006-04-11 The Procter & Gamble Company Compositions and methods for body weight management
AU2005242170B2 (en) * 2000-06-26 2008-12-18 The Procter & Gamble Company Compositions and methods for body weight management
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
US6635015B2 (en) * 2001-04-20 2003-10-21 The Procter & Gamble Company Body weight management system
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
WO2003018529A1 (en) * 2001-08-24 2003-03-06 Girouard Michael P Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
US20040157816A1 (en) * 2002-08-26 2004-08-12 Girouard Michael P. Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
CA2543393A1 (en) * 2002-11-20 2004-06-03 Michael P. Girouard Combination of monounsaturated fatty acids and estrogen, and their use
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
WO2006110172A2 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Steroid analogs and characterization and treatment methods
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7528791B2 (en) * 2005-08-08 2009-05-05 Wistron Neweb Corporation Antenna structure having a feed element formed on an opposite surface of a substrate from a ground portion and a radiating element
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2008147373A2 (en) * 2006-06-26 2008-12-04 Manhattan Pharmaceuticals, Inc. Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2302449B1 (es) * 2006-10-30 2009-06-12 Oleoyl-Estrone Developments, S.L. Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2085089A1 (en) * 2008-02-01 2009-08-05 KTB-Tumorforschungs GmbH Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013102207A1 (en) * 2011-12-30 2013-07-04 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265976A (en) * 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
GB531178A (en) * 1938-07-02 1940-12-31 Chem Ind Basel Manufacture of new esters of the oxy-stilbene series
JPH0610127B2 (ja) * 1985-02-09 1994-02-09 ライオン株式会社 養毛料
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control

Also Published As

Publication number Publication date
ES2192221T3 (es) 2003-10-01
US5798348A (en) 1998-08-25
EP0771817B1 (en) 2003-03-26
ATE235505T1 (de) 2003-04-15
EP0771817A2 (en) 1997-05-07
EP0771817A3 (en) 1999-04-14
DE69626927T2 (de) 2003-11-20
DK0771817T3 (da) 2003-07-28
DE69626927D1 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
PT771817E (pt) Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
McMurchie et al. Incorporation and effects of dietary eicosapentaenoate (20: 5 (n− 3)) on plasma and erythrocyte lipids of the marmoset following dietary supplementation with differing levels of linoleic acid
Zampolli et al. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models
Wargovich et al. Calcium inhibits the damaging and compensatory proliferative effects of fatty acids on mouse colon epithelium
Bourre et al. High dietary fish oil alters the brain polyunsaturated fatty acid composition
BR9803195A (pt) Produto alimentìcio à base de gordura,e, pasta de gordura amarela de espalhar.
BR0307101A (pt) Fracionamento de ésteres de fitosterol em óleo
ES2074734T5 (es) Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
AU2671292A (en) Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases
EP1072249A3 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
KR960010832B1 (ko) 필수지방산 합성물(Essential Fatty Acid Compositins)
Williams Dietary interventions affecting chylomicron and chylomicron remnant clearance
Williams et al. Effects of dietary fat level on pantothenate depletion and liver fatty acid composition in the rat
ATE93722T1 (de) Omega-3-fettsaeurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
ATE193006T1 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
Kiitchevsky et al. Serum and liver lipids of rats fed cocoa butter, corn oil, palm kernel oil, coconut oil and cholesterol
Larue et al. Effect of the removal of olfactory bulbs upon hyperphagia and obesity induced in rats by VMH lesion
US5484611A (en) Method of producing a fatty acid
Leaf et al. Experimental studies on antiarrhythmic and antiseizure effects of polyunsaturated fatty acids in excitable tissues
WO2004045560A3 (en) Combination of monounsaturated fatty acids and estogen, and their use
KR910005872A (ko) 간염 예방 치료제
Peterson et al. Effects of dietary sterols and sterol esters on plasma and liver cholesterol in the chick
KR920021151A (ko) 면역억제특성을 갖는 약제학적 조성물을 제조하기 위한 인지질 유도체의 용도
RU2052947C1 (ru) Масложировой продукт, имеющий иммуностимулирующие свойства
Craig et al. Nutritional properties of Canadian canbra oil